223 related articles for article (PubMed ID: 30058054)
1. Activation of histamine H
He GH; Ding JQ; Zhang X; Xu WM; Lin XQ; Huang MJ; Feng J; Wang P; Cai WK
J Mol Med (Berl); 2018 Sep; 96(9):951-964. PubMed ID: 30058054
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-134 prevents the progression of esophageal squamous cell carcinoma via the PLXNA1-mediated MAPK signalling pathway.
Wang WW; Zhao ZH; Wang L; Li P; Chen KS; Zhang JY; Li WC; Jiang GZ; Li XN
EBioMedicine; 2019 Aug; 46():66-78. PubMed ID: 31383552
[TBL] [Abstract][Full Text] [Related]
3. Blocking FGFR4 exerts distinct anti-tumorigenic effects in esophageal squamous cell carcinoma.
Xin Z; Song X; Jiang B; Gongsun X; Song L; Qin Q; Wang Q; Shi M; Liu X
Thorac Cancer; 2018 Dec; 9(12):1687-1698. PubMed ID: 30267473
[TBL] [Abstract][Full Text] [Related]
4. LncRNA-TUSC7/miR-224 affected chemotherapy resistance of esophageal squamous cell carcinoma by competitively regulating DESC1.
Chang ZW; Jia YX; Zhang WJ; Song LJ; Gao M; Li MJ; Zhao RH; Li J; Zhong YL; Sun QZ; Qin YR
J Exp Clin Cancer Res; 2018 Mar; 37(1):56. PubMed ID: 29530057
[TBL] [Abstract][Full Text] [Related]
5. The transcription factor LEF1 promotes tumorigenicity and activates the TGF-β signaling pathway in esophageal squamous cell carcinoma.
Zhao Y; Zhu J; Shi B; Wang X; Lu Q; Li C; Chen H
J Exp Clin Cancer Res; 2019 Jul; 38(1):304. PubMed ID: 31296250
[TBL] [Abstract][Full Text] [Related]
6. High expression of Collagen Triple Helix Repeat Containing 1 (CTHRC1) facilitates progression of oesophageal squamous cell carcinoma through MAPK/MEK/ERK/FRA-1 activation.
Wang C; Li Z; Shao F; Yang X; Feng X; Shi S; Gao Y; He J
J Exp Clin Cancer Res; 2017 Jun; 36(1):84. PubMed ID: 28645305
[TBL] [Abstract][Full Text] [Related]
7. miR-516b functions as a tumor suppressor by directly modulating CCNG1 expression in esophageal squamous cell carcinoma.
Zhao Y; Wang Y; Xing G
Biomed Pharmacother; 2018 Oct; 106():1650-1660. PubMed ID: 30119241
[TBL] [Abstract][Full Text] [Related]
8. WISP2 exhibits its potential antitumor activity via targeting ERK and E-cadherin pathways in esophageal cancer cells.
Chai DM; Qin YZ; Wu SW; Ma L; Tan YY; Yong X; Wang XL; Wang ZP; Tao YS
J Exp Clin Cancer Res; 2019 Feb; 38(1):102. PubMed ID: 30808397
[TBL] [Abstract][Full Text] [Related]
9. Co-targeting PLK1 and mTOR induces synergistic inhibitory effects against esophageal squamous cell carcinoma.
Liu TT; Yang KX; Yu J; Cao YY; Ren JS; Hao JJ; Pan BQ; Ma S; Yang LY; Cai Y; Wang MR; Zhang Y
J Mol Med (Berl); 2018 Aug; 96(8):807-817. PubMed ID: 29959473
[TBL] [Abstract][Full Text] [Related]
10. Potential therapeutic effect of targeting glycogen synthase kinase 3β in esophageal squamous cell carcinoma.
Bolidong D; Domoto T; Uehara M; Sabit H; Okumura T; Endo Y; Nakada M; Ninomiya I; Miyashita T; Wong RW; Minamoto T
Sci Rep; 2020 Jul; 10(1):11807. PubMed ID: 32678196
[TBL] [Abstract][Full Text] [Related]
11. TOPK promotes metastasis of esophageal squamous cell carcinoma by activating the Src/GSK3β/STAT3 signaling pathway via γ-catenin.
Jiang Y; Zhang J; Zhao J; Li Z; Chen H; Qiao Y; Chen X; Liu K; Dong Z
BMC Cancer; 2019 Dec; 19(1):1264. PubMed ID: 31888532
[TBL] [Abstract][Full Text] [Related]
12. Plasma miR-185 is decreased in patients with esophageal squamous cell carcinoma and might suppress tumor migration and invasion by targeting RAGE.
Jing R; Chen W; Wang H; Ju S; Cong H; Sun B; Jin Q; Chu S; Xu L; Cui M
Am J Physiol Gastrointest Liver Physiol; 2015 Nov; 309(9):G719-29. PubMed ID: 26316588
[TBL] [Abstract][Full Text] [Related]
13. circGSK3β promotes metastasis in esophageal squamous cell carcinoma by augmenting β-catenin signaling.
Hu X; Wu D; He X; Zhao H; He Z; Lin J; Wang K; Wang W; Pan Z; Lin H; Wang M
Mol Cancer; 2019 Nov; 18(1):160. PubMed ID: 31722716
[TBL] [Abstract][Full Text] [Related]
14. Targeting p21-activated kinase 1 inhibits growth and metastasis via Raf1/MEK1/ERK signaling in esophageal squamous cell carcinoma cells.
Chen L; Bi S; Hou J; Zhao Z; Wang C; Xie S
Cell Commun Signal; 2019 Apr; 17(1):31. PubMed ID: 30971268
[TBL] [Abstract][Full Text] [Related]
15. Triptolide prevents proliferation and migration of Esophageal Squamous Cell Cancer via MAPK/ERK signaling pathway.
Yanchun M; Yi W; Lu W; Yu Q; Jian Y; Pengzhou K; Ting Y; Hongyi L; Fang W; Xiaolong C; Yongping C
Eur J Pharmacol; 2019 May; 851():43-51. PubMed ID: 30779917
[TBL] [Abstract][Full Text] [Related]
16. Aberrant promoter 2 methylation‑mediated downregulation of protein tyrosine phosphatase, non‑receptor type 6, is associated with progression of esophageal squamous cell carcinoma.
Liu L; Zhang S; Liu X; Liu J
Mol Med Rep; 2019 Apr; 19(4):3273-3282. PubMed ID: 30816454
[TBL] [Abstract][Full Text] [Related]
17. Functional Role of a Novel Long Noncoding RNA
Lin C; Zhang S; Wang Y; Wang Y; Nice E; Guo C; Zhang E; Yu L; Li M; Liu C; Hu L; Hao J; Qi W; Xu H
Clin Cancer Res; 2018 Jan; 24(2):486-498. PubMed ID: 29101304
[No Abstract] [Full Text] [Related]
18. Obesity Potentiates Esophageal Squamous Cell Carcinoma Growth and Invasion by AMPK-YAP Pathway.
Liu JH; Wu QF; Fu JK; Che XM; Li HJ
J Immunol Res; 2020; 2020():6765474. PubMed ID: 33381605
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-384 inhibits the progression of esophageal squamous cell carcinoma through blockade of the LIMK1/cofilin signaling pathway by binding to LIMK1.
Yu HX; Wang XL; Zhang LN; Zhang J; Zhao W
Biomed Pharmacother; 2019 Jan; 109():751-761. PubMed ID: 30551528
[TBL] [Abstract][Full Text] [Related]
20. Suppressor of cytokine signaling-1 gene therapy induces potent antitumor effect in patient-derived esophageal squamous cell carcinoma xenograft mice.
Sugase T; Takahashi T; Serada S; Nakatsuka R; Fujimoto M; Ohkawara T; Hara H; Nishigaki T; Tanaka K; Miyazaki Y; Makino T; Kurokawa Y; Yamasaki M; Nakajima K; Takiguchi S; Kishimoto T; Mori M; Doki Y; Naka T
Int J Cancer; 2017 Jun; 140(11):2608-2621. PubMed ID: 28233302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
